Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
If you wish to exercise any of the following rights, please contact our privacy team using the contact details provided in Section 1
GLP-1 receptor agonists work by stimulating insulin release in response to high blood sugar levels, inhibiting glucagon release after meals, and slowing gastric emptying to help decrease appetite and food intake
Our goal is to reduce suffering and transform the health system in America one professional at a time
Vegan, gluten-free, and made in the USA
When compared against the average risk score for a diabetic member, diabetic members not taking GLP-1s are riskier than average, while those taking GLP-1s were less risky than averageand, by a wider margin
